Rocket


Overview
Financials
News + Filings
Key Docs
Ownership





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

ASLAN Pharmaceuticals Ltd (ASLN)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
 
In millions, except per share itemsDec-31-20Dec-31-19
   6-K6-K
Revenues  0.03.0
            Revenue growth  -100.0% 
Cost of goods sold  0.00.4
Gross profit  0.02.6
            Gross margin   86.4%
Selling, general and administrative   [+]7.28.5
Research and development  9.316.6
Other operating expenses   23.1
EBIT   [+]-16.5-45.6
            EBIT margin   -1519.3%
Interest income  0.00.2
Other income (expense), net  -0.5-1.2
Pre-tax income  -17.0-46.7
Income taxes  0.00.4
            Tax rate  0.0% 
Minority interest  -1.5-0.1
Net income  -17.0-47.1
            Net margin   -1568.9%
   
Basic EPS   [+]($0.40)($1.45)
Diluted EPS   [+]($0.40)($1.45)
   
Shares outstanding (basic)   [+]42.432.5
Shares outstanding (diluted)   [+]42.432.5
   
EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.  

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy